search button
Open Access

Glycyrrhizin regulates the HMGB1/P38MAPK signalling pathway in status epilepticus

  • Authors:
    • Zhong Luo
    • Meng Xu
    • Linhai Zhang
    • Haiqing Zhang
    • Zucai Xu
    • Zhongxiang Xu

  • View Affiliations

  • Published online on: January 5, 2023     https://doi.org/10.3892/mmr.2023.12932
  • Article Number: 45

  • Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In recent decades, studies have reported that inflammation serves key roles in epilepsy and that high mobility group box protein‑1 (HMGB1) may be involved in status epilepticus. However, it has not been reported whether HMGB1 participates in the pathogenesis of status epilepticus through the regulation of the p38 mitogen‑activated protein kinase (p38MAPK) signalling pathway. In the present study, Sprague‑Dawley rats were randomly divided into four groups as follows: Control, status epilepticus (SE), dimethyl sulfoxide treatment (DMSO + SE), and glycyrrhizin treatment (GL + SE) groups. Behavioural changes were then evaluated using the Racine score. In the hippocampus, the protein expression levels of HMGB1 were assessed using western blotting, the neuronal damage was evaluated using haematoxylin and eosin staining and transmission electron microscopy, and the activation of microglia was assessed using immunochemistry and immunofluorescence. The results demonstrated that, in the hippocampal region, HMGB1 existed in neurons and astrocytes and the protein expression levels of HMGB1, p38MAPK and phosphorylated‑p38MAPK were significantly inhibited after treatment with GL. Furthermore, GL could alleviate neuronal injury in the CA1 region of the hippocampus and prevented HMGB1 translocation from the nucleus into the cytoplasm in these areas. These findings expand the understanding of how HMGB1 may participate in SE and lay a foundation for evaluation of HMGB1 as a drug target.
View Figures
View References

Related Articles

Journal Cover

February-2023
Volume 27 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 7.6
  • CiteScore Rank: Q1: #82/347 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.647
  • SCImago Journal Rank (SJR): 0.781
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Luo Z, Xu M, Zhang L, Zhang H, Xu Z and Xu Z: Glycyrrhizin regulates the HMGB1/P38MAPK signalling pathway in status epilepticus. Mol Med Rep 27: 45, 2023.
APA
Luo, Z., Xu, M., Zhang, L., Zhang, H., Xu, Z., & Xu, Z. (2023). Glycyrrhizin regulates the HMGB1/P38MAPK signalling pathway in status epilepticus. Molecular Medicine Reports, 27, 45. https://doi.org/10.3892/mmr.2023.12932
MLA
Luo, Z., Xu, M., Zhang, L., Zhang, H., Xu, Z., Xu, Z."Glycyrrhizin regulates the HMGB1/P38MAPK signalling pathway in status epilepticus". Molecular Medicine Reports 27.2 (2023): 45.
Chicago
Luo, Z., Xu, M., Zhang, L., Zhang, H., Xu, Z., Xu, Z."Glycyrrhizin regulates the HMGB1/P38MAPK signalling pathway in status epilepticus". Molecular Medicine Reports 27, no. 2 (2023): 45. https://doi.org/10.3892/mmr.2023.12932